ARTBIO

Cambridge, United States

ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines.

$132.0M raised

Jul 2025

Series B

Top Investors

B CapitalOmega FundsThird Rock VenturesSofinnova InvestmentsF-Prime

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has ARTBIO raised?

ARTBIO has raised $132.0M in total funding. The most recent round was Series B. The last funding was announced in July 2025.

Who are ARTBIO's investors?

ARTBIO's investors include B Capital, Omega Funds, Third Rock Ventures, Sofinnova Investments, F-Prime.

Where is ARTBIO headquartered?

ARTBIO is headquartered in Cambridge, United States.

What does ARTBIO do?

ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines.

What stage is ARTBIO at?

ARTBIO is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated July 29, 2025.

MLA

"ARTBIO — Funding & Investors." VCBacked, July 29, 2025, https://www.vcbacked.co/company/artbio. Accessed June 3, 2026.

APA

VCBacked. (2025). ARTBIO — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/artbio

Wikipedia (cite web)

{{cite web |title=ARTBIO — Funding & Investors |url=https://www.vcbacked.co/company/artbio |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated July 29, 2025.